Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription


2 Am J Hematol
1 Am J Surg Pathol
3 Blood
2 BMC Cancer
2 Bone Marrow Transplant
1 Br J Haematol
3 Haematologica
1 Int J Cancer
1 J Am Acad Dermatol
3 Leuk Lymphoma
1 Leukemia
1 Oncology (Williston Park)
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Hematol

  1. LIM JQ, Huang D, Chan JY, Laurensia Y, et al
    A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort.
    Am J Hematol. 2022 Jun 20. doi: 10.1002/ajh.26636.
    PubMed         Abstract available

  2. SEEGOBIN K, Li Z, Alhaj Moustafa M, Majeed U, et al
    Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003-2018).
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26635.
    PubMed         Abstract available

    Am J Surg Pathol

  3. CRADDOCK AP, Kane WJ, Raghavan SS, Williams ES, et al
    Use of Ultrasensitive RNA In Situ Hybridization for Determining Clonality in Cutaneous B-Cell Lymphomas and Lymphoid Hyperplasia Decreases Subsequent Use of Molecular Testing and Is Cost-effective.
    Am J Surg Pathol. 2022;46:956-962.
    PubMed         Abstract available


  4. FERRERO S, Grimaldi D, Genuardi E, Drandi D, et al
    Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma.
    Blood. 2022 Jun 23. pii: 485688. doi: 10.1182/blood.2021014270.
    PubMed         Abstract available

    Smart salvage treatment for Hodgkin lymphoma.
    Blood. 2022;139:3563-3564.

  6. BACKER K, Wang HY
    Florid reactive follicular hyperplasia with exuberant HHV8 infection.
    Blood. 2022;139:3558.

    BMC Cancer

  7. LARA S, Heilig J, Virtanen A, Kleinau S, et al
    Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
    BMC Cancer. 2022;22:678.
    PubMed         Abstract available

  8. VAN HEEK L, Stuka C, Kaul H, Muller H, et al
    Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
    BMC Cancer. 2022;22:672.
    PubMed         Abstract available

    Bone Marrow Transplant

  9. YANG JC, Scordo M, Chau KW, Sauter CS, et al
    Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy.
    Bone Marrow Transplant. 2022;57:1038-1041.

  10. SCHENONE L, Houillier C, Tanguy ML, Choquet S, et al
    Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone Marrow Transplant. 2022 Apr 14. pii: 10.1038/s41409-022-01648.
    PubMed         Abstract available

    Br J Haematol

  11. MIAN A, Bhattarai N, Sheu M, Ondrejka SL, et al
    Sequential loss of B-cell target antigens in multiply relapsed high-grade B-cell lymphoma treated with targeted therapies.
    Br J Haematol. 2022 Jun 22. doi: 10.1111/bjh.18333.


  12. FUJI S, Yasunaga JI, Watanabe E, Matsuoka M, et al
    Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation.
    Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.281175.
    PubMed         Abstract available

  13. ISAEV K, Liu T, Bakhtiari M, Tong K, et al
    In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
    Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.280900.
    PubMed         Abstract available

  14. VELOZA L, Cavalieri D, Missiaglia E, Ledoux-Pilon A, et al
    Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
    Haematologica. 2022 Jun 16. doi: 10.3324/haematol.2022.281226.
    PubMed         Abstract available

    Int J Cancer

  15. YARMOLINSKY J, Amos CI, Hung RJ, Moreno V, et al
    Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34180.
    PubMed         Abstract available

    J Am Acad Dermatol

  16. QUERFELD C, Kim YH, Guitart J, Scarisbrick J, et al
    Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: A phase 2 extension study.
    J Am Acad Dermatol. 2022;87:209-211.

    Leuk Lymphoma

  17. CHAHAL M, Hayden A, Savage KJ, Villa D, et al
    Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma.
    Leuk Lymphoma. 2022 Jun 24:1-4. doi: 10.1080/10428194.2022.2087071.

  18. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.

  19. SYMES E, Wang P, Lager AM, Bishop MR, et al
    TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.


  20. THUS YJ, Eldering E, Kater AP, Spaargaren M, et al
    Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Leukemia. 2022 Jun 20. pii: 10.1038/s41375-022-01627.
    PubMed         Abstract available

    Oncology (Williston Park)

  21. KESIREDDY M, Lunning M
    Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".
    Oncology (Williston Park). 2022;36:366-375.
    PubMed         Abstract available

    PLoS One

  22. HAYAKAWA J, Seki T, Kawazoe Y, Ohe K, et al
    Pathway importance by graph convolutional network and Shapley additive explanations in gene expression phenotype of diffuse large B-cell lymphoma.
    PLoS One. 2022;17:e0269570.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.